Description

Scope of the Report:

The global Pharmaceutical Contract Manufacturing and Contract market is valued at 74220 million USD in 2018 and is expected to reach 94040 million USD by the end of 2024, growing at a CAGR of 6.1% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Pharmaceutical Contract Manufacturing and Contract.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Pharmaceutical Contract Manufacturing and Contract market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Pharmaceutical Contract Manufacturing and Contract market by product type and applications/end industries.

Market Segment by Companies, this report covers

Catalent
AbbVie
Boehringer Ingelheim
Thermo Fisher Scientific
Aenova
Lonza
Nipro Corp
Recipharm
Fareva
Baxter
Piramal
Zhejiang Hisun
Sopharma
Jubilant
Mylan
Shandong Xinhua
Famar
Zhejiang Huahai
Dr. Reddy’s
Vetter

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Oral
Injectable
API
Other

The proportion of API Manufacturing in 2018 is about 73%, and the proportion is in decreasing trend from 2014 to 2018. However, the Injectable segment is the fastest growing segment.

Market Segment by Application

s, can be divided into
Small Medium Enterprise
Large Enterprise

The most proportion of pharmaceutical contract manufacturing & contract is used for Large Enterprise, and the proportion in 2018 is 60%.